Back to Search
Start Over
Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience
- Source :
- Ocular Oncology and Pathology. 5:139-146
- Publication Year :
- 2018
- Publisher :
- S. Karger AG, 2018.
-
Abstract
- Purpose: To report our 5-year experience with intra-arterial chemotherapy (IAC) in the intravitreal chemotherapy (IvitC) era. Methods: Retrospective review of retinoblastoma treated with primary unilateral IAC in the IvitC era (2012–2017). Results: There were 34 eyes treated with IAC alone versus 20 eyes treated with IAC plus IvitC for vitreous seeds. IAC (IAC alone vs. IAC plus IvitC) consisted of melphalan (41 vs. 10%) or melphalan plus topotecan (59 vs. 90%, p = 0.03). IvitC consisted of melphalan (60%) or melphalan plus topotecan (40%). Tumor control and globe salvage were achieved in 100% of group B and C eyes without IvitC. Despite more extensive vitreous seeds in the IvitC group (p < 0.01), comparison of IAC alone versus IAC plus IvitC revealed no difference in tumor control for group D (88 vs. 69%, p = 0.36) or group E (67 vs. 100%, p = 0.25) and no difference in globe salvage for group D (88 vs. 69%, p = 0.36) or group E (58 vs. 57%, p = 0.39). Conclusions: IAC is effective as primary therapy for unilateral group B, C, D, and E retinoblastoma. IvitC is an important adjuvant therapy to achieve comparable globe salvage rates for group D and E eyes with persistent active vitreous seeds.
- Subjects :
- Melphalan
Original Paper
medicine.medical_specialty
Chemotherapy
genetic structures
Retinoblastoma
business.industry
medicine.medical_treatment
Intra arterial chemotherapy
Cancer
medicine.disease
eye diseases
Group B
Surgery
03 medical and health sciences
0302 clinical medicine
030220 oncology & carcinogenesis
030221 ophthalmology & optometry
medicine
Adjuvant therapy
Topotecan
sense organs
business
General Nursing
medicine.drug
Subjects
Details
- ISSN :
- 22964657 and 22964681
- Volume :
- 5
- Database :
- OpenAIRE
- Journal :
- Ocular Oncology and Pathology
- Accession number :
- edsair.doi.dedup.....106cf08bf811074bf1cfcd0462c47410